Histology is more ιmportant than persistent anti-Tg antibodies for progression of differentiated thyroid cancer.
| Title: | Histology is more ιmportant than persistent anti-Tg antibodies for progression of differentiated thyroid cancer. |
|---|---|
| Authors: | Karapanou O; Department of Endocrinology Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece.; Saltiki K; Endocrine Unit, Dept Clinical Therapeutics, Medical School National Kapodistrian University, Athens, Greece.; Simeakis G; Endocrine Unit, Dept Clinical Therapeutics, Medical School National Kapodistrian University, Athens, Greece.; Botoula E; Department of Endocrinology Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece.; Tsagarakis S; Department of Endocrinology Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece.; Alevizaki M; Endocrine Unit, Dept Clinical Therapeutics, Medical School National Kapodistrian University, Athens, Greece.; Vlassopoulou B; Department of Endocrinology Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece. |
| Source: | Clinical endocrinology [Clin Endocrinol (Oxf)] 2021 Jul; Vol. 95 (1), pp. 217-223. Date of Electronic Publication: 2021 Mar 21. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Blackwell Publishing Country of Publication: England NLM ID: 0346653 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2265 (Electronic) Linking ISSN: 03000664 NLM ISO Abbreviation: Clin Endocrinol (Oxf) Subsets: MEDLINE |
| Imprint Name(s): | Publication: : Oxford : Blackwell Publishing; Original Publication: Oxford, Blackwell Scientific Publications. |
| MeSH Terms: | Iodine Radioisotopes*/therapeutic use ; Thyroid Neoplasms*/surgery; Female ; Humans ; Retrospective Studies ; Thyroglobulin ; Thyroidectomy |
| Abstract: | Context: Anti-thyroglobulin antibodies (anti-Tg), present in 20%-25% of differentiated thyroid cancer (DTC) patients, interfere with thyroglobulin measurements posing a challenge in the follow-up.; Objectives: The aim of this study was to identify clinical-histological factors that may affect anti-Tg persistence and disease outcome in DTC with positive anti-Tg.; Methods: We retrospectively studied 234 DTC patients, with positive anti-Tg at diagnosis (females: 82.1%, age at diagnosis: 46.0 ± 14.4 yrs, median follow-up: 5 yrs (1.5-32 yrs). 221/234 (94.4%) received radioiodine (RAI) ablation. Patients were divided into two subgroups: those whose anti-Tg became undetectable (anti-Tg-NEG) and those whose anti-Tg remained positive (anti-Tg-POS) at the end of the follow-up period.; Results: Anti-Tg-POS patients (n = 80, 34.2%) compared to anti-Tg-NEG (n = 154, 65.8%) had more frequently lymph node infiltration (36.3% vs 20.1%, P = .01), extrathyroidal extension (ETE, 35.0% vs 22.1%, P = .04), poorly differentiated DTC and increased tumour size (P ≤ .004). They received higher total RAI dose (P |
| References: | Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601-607.; Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645-649.; Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.; Pedersen IB, Knudsen N, Jorgensen T, Perrild H, Ovesen L, Laurberg P. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxf). 2003;58:36-42.; Feldt-Rasmussen U, Rasmussen AK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens). 2010;9:109-117.; Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:5566-5575.; Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153:49-55.; Adil A, Jafri RA, Waqar A, et al. Frequency and clinical importance of anti-Tg auto-antibodies (ATG). J Coll Physicians Surg Pak. 2003;13:504-506.; Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002;57:215-221.; Tsushima Y, Miyauchi A, Ito Y, et al. Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J. 2013;60:871-876.; Larbre H, Schvartz C, Schneider N, et al. Positive antithyroglobulin antibodies in patients with differentiated thyroid carcinoma. What significance? Ann Endocrinol (Paris). 2000;61:422-427.; Durante C, Tognini S, Montesano T, et al. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid. 2014;24:1139-1145.; Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139:346-351.; Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668-3673.; Pedrazzini L, Baroli A, Lomuscio G, Marzoli L. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study. Minerva Endocrinol. 2009;34:195-203.; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.; Jo K, Kim MH, Ha J, et al. Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2017;87:292-299.; Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:1054-1067.; Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011;96:3615-3627.; Hsieh CJ, Wang PW. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid. 2014;24:488-493.; Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93:4683-4689.; Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994;4:199-202.; Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG. The de novo detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence. Thyroid. 2020;30:1490-1495.; Hirsch D, Gorshtein A, Robenshtok E, et al. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J Clin Endocrinol Metab. 2018;103:469-476.; Cao CJ, Dou CY, Lian J, et al. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. Oncol Lett. 2018;15:8141-8148.; Slook O, Levy S, Slutzky-Shraga I, et al. Long-term outcomes and prognostic factors in patients with differentiated thyroid carcinoma and bone metastases. Endocr Pract. 2019;25:427-437.; Kim SJ, Lee SW, Pak K, Shim SR. Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab. Endocr Relat Cancer. 2018;25:643-652.; Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem. 2008;54:1796-1804.; Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med. 2012;60:1157-1163.; Ringel MD. Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. J Clin Endocrinol Metab. 2004;89:29-32.; Thomas D, Liakos V, Vassiliou E, Hatzimarkou F, Tsatsoulis A, Kaldrimides P. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation. J Endocrinol Invest. 2007;30:173-180. |
| Contributed Indexing: | Keywords: anti-thyroglobulin antibodies; differentiated thyroid cancer; papillary; thyroglobulin |
| Substance Nomenclature: | 0 (Iodine Radioisotopes); 9010-34-8 (Thyroglobulin) |
| Entry Date(s): | Date Created: 20210308 Date Completed: 20211027 Latest Revision: 20211027 |
| Update Code: | 20260130 |
| DOI: | 10.1111/cen.14456 |
| PMID: | 33682167 |
| Database: | MEDLINE |
Journal Article